ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
Status:
Withdrawn
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the effects of ONC201 in combination with standard of care
radiation therapy in treating patients with glioblastoma that has come back (recurrent).
ONC201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Radiation therapy uses high energy photons to kill tumors cells and shrink tumors.
Giving ONC201 in combination with radiation therapy may help treat patients with recurrent
glioblastoma.
Phase:
Phase 1
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
National Cancer Institute (NCI) Oncoceutics, Inc. University of California, Los Angeles